ADC Therapeutics FY25 Revenue Consensus at $76.6M
FY25 revenue consensus $76.6M. "During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028," said Ameet Mallik, CEO of ADC Therapeutics. "This year, we look forward to multiple clinical catalysts including full results from our LOTIS-5 and LOTIS-7 2L+ DLBCL trials, as well as potentially from the ongoing Phase 2 indolent lymphoma IITs. Assuming positive results, we anticipate potential compendia inclusion for each in the first half of 2027 with LOTIS-5 regulatory approvals to follow. Taken together, we anticipate we will see an acceleration in net product revenue growth beginning in 2027." ZYNLONTA net product revenue is expected to be approximately $73M for full year 2025 compared with $69.3M for full year 2024. Fourth quarter 2025 ZYNLONTA net product revenue is expected to be approximately $22M, as compared to $16.4M in the fourth quarter of 2024, primarily reflecting variability in customer ordering. Underlying demand for ZYNLONTA in the current 3L/3L+ DLBCL indication remained broadly stable year-over-year. The company ended 2025 with cash and cash equivalents of approximately $261M which, based on current plans, is expected to provide a cash runway at least to 2028.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on ADCT
About ADCT
About the author
ADC Therapeutics Faces Securities Fraud Investigation, Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating whether ADC Therapeutics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock volatility.
- Clinical Trial Data: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome; despite positive framing, the occurrence of adverse events could tarnish the company's reputation.
- Stock Price Reaction: Following the clinical data release, ADC's stock price fell by $0.65, a 14.13% drop, closing at $3.95 per share, reflecting market concerns about the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent securities class action firm with over 85 years of experience, is dedicated to protecting investor rights, and adverse findings from the investigation could result in significant financial liabilities for the company.
ADC Therapeutics Faces Securities Fraud Investigation as Stock Drops 14.13%
- Investigation Launched: Pomerantz LLP is investigating ADC Therapeutics for potential securities fraud, which could undermine investor confidence and lead to further stock price volatility.
- Clinical Trial Data Update: On December 3, 2025, ADC released data from the LOTIS-7 trial indicating that 36.7% of patients experienced cytokine release syndrome, and while the data was presented positively, the associated risks may affect market acceptance of its products.
- Stock Price Reaction: Following the release of adverse clinical data, ADC's stock price fell by $0.65, or 14.13%, closing at $3.95 per share on December 3, 2025, reflecting market concerns about the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent securities class action firm, may initiate legal proceedings against ADC, potentially impacting shareholder interests and the company's reputation.